Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
29 Jan 2019

Salvage treatment with carfilzomib, pomalidomide and dexamethasone (KPd) is effective and safe in transplant-eligible multiple myeloma (MM) patients with refractory disease or first progression on or after treatment with bortezomib and lenalidomide, according to data from patients enrolled in the EMN02 trial.

Coffee cuts risk of HCC recurrence

6 days ago

Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation (OLT), a study has found.

Researchers analysed the coffee drinking patterns of patients prior to and following OLT for HCC in relation to disease recurrence. They examined HepG2 cells for proliferation and metastasis potential following treatment with adenosine, in the presence or absence of adenosine receptor antagonists. Other assessments included adenosine receptor expression and known adenosine‐mediated cancer pathways inclusive of MAPK and NF‐kappa B. Median follow-up duration was 45.5 months.

The study population included 90 patients (median age, 60 years; median body mass index, 26.95 kg/m2) who underwent OLT, among whom 16 (17.8 percent) had HCC recurrence after median of 11.5 months. There were 21 patients who died (23.2 percent) after a median of 16 months. Overall survival at 1, 3 and 5 years were 90 percent, 80 percent and 72.6 percent, respectively.

On multivariable Cox analysis, coffee intake after OLT had a significant beneficial effect on recurrence‐free survival (hazard ratio [HR], 0.60; 95 percent CI, 0.37–0.97; p=0.037).

Postoperative coffee intake was also associated with a marked improvement in overall survival (HR, 0.2936; 0.12–0.71; p=0.006). Notably, those who drank ≥3 cups of coffee per day had a longer survival than those who consumed less or no coffee (mean, 11.0 vs 7.48 years; p=0.029).

Based on experimental data, the beneficial effects of postoperative coffee consumption on HCC recurrence and survival might be partly related to the antagonist activity of caffeine on adenosine‐A2AR mediated growth‐promoting effects in HCC cells, as researchers pointed out.

The present data have implications for future recommendations for coffee consumption in patients following OLT for HCC, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
29 Jan 2019

Salvage treatment with carfilzomib, pomalidomide and dexamethasone (KPd) is effective and safe in transplant-eligible multiple myeloma (MM) patients with refractory disease or first progression on or after treatment with bortezomib and lenalidomide, according to data from patients enrolled in the EMN02 trial.